| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
98.16(B) |
| Last
Volume: |
1,066,779 |
Avg
Vol: |
770,880 |
| 52
Week Range: |
$692.45 - $993.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
40,708 |
84,942 |
120,351 |
283,828 |
| Total Sell Value |
$38,834,511 |
$77,255,398 |
$106,848,389 |
$220,981,114 |
| Total People Sold |
9 |
13 |
15 |
17 |
| Total Sell Transactions |
20 |
38 |
53 |
116 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2023-08-23 |
4 |
D |
$842.66 |
$14,264,548 |
D/D |
(16,928) |
27,705 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2023-08-23 |
4 |
OE |
$381.40 |
$8,819,875 |
D/D |
23,125 |
44,633 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2023-08-22 |
4 |
S |
$840.53 |
$9,810,082 |
D/D |
(11,665) |
53,100 |
|
-4% |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2023-08-21 |
4 |
D |
$833.39 |
$31,948,006 |
D/D |
(38,335) |
64,765 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2023-08-21 |
4 |
OE |
$399.66 |
$19,983,000 |
D/D |
50,000 |
103,100 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2023-08-21 |
4 |
AS |
$829.00 |
$707,137 |
D/D |
(853) |
1,247 |
|
4% |
|
| Bassler Bonnie L |
Director |
– • – |
2023-08-21 |
4 |
OE |
$391.92 |
$334,308 |
D/D |
853 |
2,100 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2023-08-10 |
4 |
AS |
$789.00 |
$673,017 |
D/D |
(853) |
1,247 |
|
7% |
|
| Bassler Bonnie L |
Director |
– • – |
2023-08-10 |
4 |
OE |
$391.92 |
$334,308 |
D/D |
853 |
2,100 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2023-08-01 |
4 |
AS |
$732.76 |
$73,659 |
D/D |
(100) |
18,647 |
|
15% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-08-01 |
4 |
AS |
$744.66 |
$186,165 |
D/D |
(250) |
20,053 |
|
15% |
|
| Ryan Arthur F |
Director |
– • – |
2023-07-03 |
4 |
AS |
$710.09 |
$71,688 |
D/D |
(100) |
18,747 |
|
15% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-07-03 |
4 |
AS |
$710.09 |
$177,523 |
D/D |
(250) |
20,303 |
|
15% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-06-01 |
4 |
AS |
$736.00 |
$184,000 |
D/D |
(250) |
20,553 |
|
14% |
|
| Ryan Arthur F |
Director |
– • – |
2023-06-01 |
4 |
AS |
$730.03 |
$73,542 |
D/D |
(100) |
18,847 |
|
14% |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2023-05-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
53,807 |
64,985 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2023-05-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
53,807 |
0 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2023-05-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,326 |
59,421 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2023-05-01 |
4 |
AS |
$802.67 |
$80,533 |
D/D |
(100) |
18,947 |
|
3% |
|
| Brown Michael S |
Director |
– • – |
2023-04-21 |
4 |
AS |
$798.42 |
$2,451,149 |
D/D |
(3,070) |
1,247 |
|
4% |
|
| Brown Michael S |
Director |
– • – |
2023-04-21 |
4 |
OE |
$520.01 |
$1,596,431 |
D/D |
3,070 |
4,317 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2023-04-03 |
4 |
AS |
$816.58 |
$81,931 |
D/D |
(100) |
19,047 |
|
-2% |
|
| Vagelos P Roy |
Director |
– • – |
2023-04-03 |
4 |
GD |
$0.00 |
$0 |
I/I |
259 |
125,493 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-04-03 |
4 |
AS |
$818.80 |
$900,680 |
D/D |
(1,100) |
20,803 |
|
-2% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-04-03 |
4 |
OE |
$372.46 |
$409,706 |
D/D |
1,100 |
21,903 |
|
- |
|
2402 Records found
|
|
Page 7 of 97 |
|
|
34.13 (3.78%) 
